Fourth Annual American College of Cardiology International Lecture. A Journey in the Interventional Field

Journal of the American College of Cardiology

Volumn 47, Issue 9, 2006, Pages 1754-1768

  Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; INTERLEUKIN 6; RAPAMYCIN; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 2; RECOMBINANT FIBROBLAST GROWTH FACTOR 4; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT VASCULOTROPIN; UNCLASSIFIED DRUG; VASCULOTROPIN 121; VASCULOTROPIN 165;

ANGIOGENESIS; ANGIOPLASTY; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORRELATION ANALYSIS; DRUG ELUTING STENT; HEART ASSIST DEVICE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MUSCLE DEVELOPMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; STEM CELL;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; CORONARY RESTENOSIS; CORONARY VESSELS; ENDOSONOGRAPHY; HEART VALVE DISEASES; HEART VALVES; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; STENTS;

EID: 33646173591     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.12.051     Document Type: Review

References (68)

1. Gruntzig A.R., Senning A., and Siegenthaler W.E. Nonoperative dilatation of coronary-artery stenosis. percutaneous transluminal coronary angioplasty. N Engl J Med 301 (1979) 61-68
2. Sigwart U., Puel J., Mirkovitch V., Joffre F., and Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 316 (1987) 701-706
3. Fischman D.L., Leon M.B., Baim D.S., et al., Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 331 (1994) 496-501
4. Serruys P.W., de Jaegere P., Kiemeneij F., et al., Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 331 (1994) 489-495
5. Sousa J.E., Costa M.A., Abizaid A., et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries. a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 103 (2001) 192-195
6. Rensing B.J., Vos J., Smits P.C., et al. Coronary restenosis elimination with a sirolimus eluting stent. first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J 22 (2001) 2125-2130
7. Serruys P.W. ARTS I- the rapamycin eluting stent; ARTS II- the rosy prophecy. Eur Heart J 23 (2002) 757-759
8. Serruys P.W., Unger F., Sousa J.E., et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 344 (2001) 1117-1124
9. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
10. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
11. Grube E., Silber S., Hauptmann K.E., et al. TAXUS I. six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107 (2003) 38-42
12. Colombo A., Drzewiecki J., Banning A., et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108 (2003) 788-794
13. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
14. Lemos P.A., Serruys P.W., van Domburg R.T., et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world". the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 109 (2004) 190-195
15. Ong A.T., Serruys P.W., Aoki J., et al. The unrestricted use of paclitaxel versus sirolimus-eluting stents for coronary artery disease in an unselected population-one year results of The Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) Registry. J Am Coll Cardiol 45 (2005) 1135-1141
16. Serruys P.W., and Lemos P. From RESEARCH to Clinical Practice. 1st edition. (2004), Taylor and Francis Group, London
17. Arampatzis C.A., Lemos P.A., Hoye A., et al. Elective sirolimus-eluting stent implantation for left main coronary artery disease. six-month angiographic follow-up and 1-year clinical outcome. Catheter Cardiovasc Interv 62 (2004) 292-296 discussion 297
18. Mercado N., Wijns W., Serruys P., et al. One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease. a meta-analysis of individual patient data from randomized clinical trials. J Thorac Cardiovasc Surg 130 (2005) 512-519
19. Serruys P.W. A.R.T.S. II. Arterial Revascularization Therapies Study, part II, of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions (2005) Paper presented at: 54th Annual Scientific Session of the American College of Cardiology; Orlando, FL
20. Serruys P.W., Ong A.T., Morice M.C., et al. Arterial revascularisation therapies study part II-sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. EuroIntervention 1 (2005) 147-156
21. Ong A.T., Serruys P.W., Mohr F.W., et al. The SYNergy between Percutaneous Coronary Intervention with TAXus™ and Cardiac Surgery (SYNTAX) study. design, rationale and run-in phase. Am Heart J (2006) In Press
22. Finkelstein A., McClean D., Kar S., et al. Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation 107 (2003) 777-784
23. Serruys P.W., Sianos G., Abizaid A., et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform. the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 46 (2005) 253-260
24. Hausleiter J., Kastrati A., Wessely R., et al. Dose-finding study with a novel drug eluting stent system with the use of an on-site, polymer-free coating with rapamycin. J Am Coll Cardiol 45 (2005) 44A
25. Hausleiter J., Kastrati A., Wessely R., et al. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J 26 (2005) 1475-1481
26. Aoki J., Serruys P.W., van Beusekom H.M., et al., The HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. Endothelial progenitor cell capture by stents coated with antibody against CD34. J Am Coll Cardiol 45 (2005) 1574-1579
27. Walter D.H., Cejna M., Diaz-Sandoval L., et al. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents. an alternative strategy for inhibition of restenosis. Circulation 110 (2004) 36-45
28. Kipshidze N.N., Iversen P., Kim H.S., et al. Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Catheter Cardiovasc Interv 61 (2004) 518-527
29. Di Mario C., Griffiths H., Goktekin O., et al. Drug-eluting bioabsorbable magnesium stent. J Interv Cardiol 17 (2004) 391-395
30. Vogt F., Stein A., Rettemeier G., et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 25 (2004) 1330-1340
31. Van Mieghem C.A., McFadden E.P., de Feyter P.J., et al. Non-invasive detection of subclinical coronary atherosclerosis coupled with assessment of changes in plaque characteristics using novel invasive imaging modalities. the Integrated Biomarker and Imaging Studay (IBIS). J Am Coll Cardiol 47 (2006) 1134-1142
32. Schaar J.A., De Korte C.L., Mastik F., et al. Characterizing vulnerable plaque features with intravascular elastography. Circulation 108 (2003) 2636-2641
33. Schaar J.A., Regar E., Mastik F., et al. Incidence of high-strain patterns in human coronary arteries. assessment with three-dimensional intravascular palpography and correlation with clinical presentation. Circulation 109 (2004) 2716-2719
34. Nair A., Kuban B.D., Tuzcu E.M., Schoenhagen P., Nissen S.E., and Vince D.G. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 106 (2002) 2200-2206
35. Rodriguez-Granillo G.A., Garcia-Garcia H.M., McFadden E.P., et al. In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. J Am Coll Cardiol 46 (2005) 2038-2042
36. Lafont A., and Libby P. The smooth muscle cell. sinner or saint in restenosis and the acute coronary syndromes?. J Am Coll Cardiol 32 (1998) 283-285
37. Serruys P.W., Hamburger J.N., Koolen J.J., et al. Total occlusion trial with angioplasty by using laser guidewire. The TOTAL trial. Eur Heart J 21 (2000) 1797-1805
38. Strauss B.H., Goldman L., Qiang B., et al. Collagenase plaque digestion for facilitating guide wire crossing in chronic total occlusions. Circulation 108 (2003) 1259-1262
39. Yang Y.M., Mehran R., Dangas G., et al. Successful use of the frontrunner catheter in the treatment of in-stent coronary chronic total occlusions. Catheter Cardiovasc Interv 63 (2004) 462-468
40. Colombo A., Mikhail G.W., Michev I., et al. Treating chronic total occlusions using subintimal tracking and reentry. the STAR Technique. Catheter Cardiovasc Interv 64 (2005) 407-411
41. Ylä-Herttuala S., and Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 9 (2003) 694-701
42. Grines C.L., Watkins M.W., Helmer G., et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105 (2002) 1291-1297
43. Grines C.L., Watkins M.W., Mahmarian J.J., et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 42 (2003) 1339-1347
44. Mann M.J., Whittemore A.D., Donaldson M.C., et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy. the PREVENT single-centre, randomised, controlled trial. Lancet 354 (1999) 1493-1498
45. Hagege A.A., Carrion C., Menasche P., et al. Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathy. Lancet 361 (2003) 491-492
46. Reinecke H., MacDonald G.H., Hauschka S.D., and Murry C.E. Electromechanical coupling between skeletal and cardiac muscle. Implications for infarct repair. J Cell Biol 149 (2000) 731-740
47. Menasche P., Hagege A.A., Vilquin J.T., et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 41 (2003) 1078-1083
48. Pagani F.D., DerSimonian H., Zawadzka A., et al. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. J Am Coll Cardiol 41 (2003) 879-888
49. Smits P.C., van Geuns R.J., Poldermans D., et al. Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure. clinical experience with six-month follow-up. J Am Coll Cardiol 42 (2003) 2063-2069
50. Herreros J., Prosper F., Perez A., et al. Autologous intramyocardial injection of cultured skeletal muscle-derived stem cells in patients with non-acute myocardial infarction. Eur Heart J 24 (2003) 2012-2020
51. Siminiak T., Kalawski R., Fiszer D., et al. Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury. phase I clinical study with 12 months of follow-up. Am Heart J 148 (2004) 531-537
52. Steendijk P., Smits P.C., Valgimigli M., et al. Intramyocardial injection of autologous skeletal myoblasts in patients with ischemic heart failure. Long-term follow-up with pressure-volume loops. Nat Clin Pract Cardiovasc Med 3 Suppl 1 (2006) S94-S100
53. Yeh E.T., Zhang S., Wu H.D., Korbling M., Willerson J.T., and Estrov Z. Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation 108 (2003) 2070-2073
54. Murry C.E., Soonpaa M.H., Reinecke H., et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428 (2004) 664-668
55. Lapidos K.A., Chen Y.E., Earley J.U., et al. Transplanted hematopoietic stem cells demonstrate impaired sarcoglycan expression after engraftment into cardiac and skeletal muscle. J Clin Invest 114 (2004) 1577-1585
56. Strauer B.E., Brehm M., Zeus T., et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106 (2002) 1913-1918
57. Assmus B., Schachinger V., Teupe C., et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 106 (2002) 3009-3017
58. Schachinger V., Assmus B., Britten M.B., et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction. final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 44 (2004) 1690-1699
59. Wollert K.C., Meyer G.P., Lotz J., et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction. the BOOST randomised controlled clinical trial. Lancet 364 (2004) 141-148
60. Bartunek J., Vanderheyden M., Vandekerckhove B., et al. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction. feasibility and safety. Circulation 112 (2005) 1178-1183
61. Ince H., Petzsch M., Kleine H.D., et al. Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI). Circulation 112 (2005) 3097-3106
62. Schachinger V. Intracoronary infusion of bone marrow-derived progenitor cells in acute myocardial infarction. a randomized, double-blind, placebo-controlled multicenter trial (REPAIR-AMI). Late-breaking clinical trial reported at the Plenary Scientific Sessions of the American Heart Association (2005) Dallas, TX
63. Lunde K. Effects on left ventricular function by intracoronary injections of autologous mononuclear bone marrow cells in acute anterior wall myocardial infarction. the ASTAMI randomized controlled trial. Late-breaking clinical trial reported at the Plenary Scientific Sessions of the American Heart Association (2005) Dallas, TX
64. Janssens S., Dubois C., Bogaert J., et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction. double-blind, randomised controlled trial. Lancet 367 (2006) 113-121
65. Zohlnhofer D., Ott I., Mehilli J., et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction. a randomized controlled trial. JAMA 295 (2006) 1003-1010
66. Beltrami A.P., Barlucchi L., Torella D., et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114 (2003) 763-776
67. Cribier A., Eltchaninoff H., Tron C., et al. Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. J Am Coll Cardiol 43 (2004) 698-703
68. Khambadkone S., and Bonhoeffer P. Nonsurgical pulmonary valve replacement. why, when, and how?. Catheter Cardiovasc Interv 62 (2004) 401-408